Invox Pharma Limited

F-star Therapeutics, Inc.

Jose Munoz-Olaya

Mihriban Tuna

Francisca Wollerton

Matthew Lakins

Neil Brewis

Remi Fertin

Alexander Koers

Sarka Pechouckova

Sarah Batey

Claire Reader

The present application relates to antibody molecules that bind both PD-L1 and CD 137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.

Antibody molecules that bind PD-L1 and CD137

The present application relates to antibody molecules that bind mesothelin (MSLN). The antibody molecules find application in the treatment and diagnosis of diseases and disorders, such as cancer.

Anti-mesothelin antibodies

The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of the antibody molecule. The antibody molecules find application in the treatment of cancer, for example.

Mesothelin and CD137 binding molecules

The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Fc binding fragments comprising a CD137 antigen-binding site

Growing community of inventors

Cambridge, United Kingdom

Jose Munoz-Olaya